Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Exclusion Criteria

• •Inflammatory carcinoma or stage I, II or IV breast cancer disease.
• •Males.
• •Active infection.
• •Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma adequately treated. Other previous neoplasms are allowed if diagnosed and treated more than 5 years before study registration.
• •Concomitant serious disease provoking organ failure (heart, renal, hepatic, respiratory).
• •Pre-existing motor or sensorial neuropathy \> grade 1.
• •Inability for treatment compliance.
• •History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin K.
• •History of arrhythmias or congestive heart failure, even when controlled; or active cardiac blocking of second or third grade.
• •History of myocardial infarction in the previous 6 months.
• •Hypertension not controlled.
• •Pregnant or lactating women.